# F. No. MED-16028/2/2024-eoffice Government of India Directorate General of Health Services Central Drugs Standard Control Organisation (Medical Devices Division)

FDA Bhawan, Kotla Road, New Delhi – 110002 Dated: 21 NCT 2025

#### **Notice**

Subject: Draft Guidance Document on conduct of Medical Device Software under MDR,2017. - Reg.

The Medical Device Software are regulated under the Medical Devices Rules, 2017 and sale & distribution its import/manufacture for in the country.

In order to have Specific regulatory requirements for Medical Device Software and to align the requirements with globally harmonized practices, a draft of the Guidance Document on Medical Device Software is prepared to bring more clarity on the regulatory aspects for Medical Device Software. This guidance documents provides scope, definition, Classification, standards, requirements of technical documents & Quality Management system applicable for Medical Device Software. The applicants may refer this documents while submission of application for grant of licence to manufacture or import Medical Device Software for sale & distribution in the country.

The draft guidance document is attached for ready reference and all concerned stakeholders are requested to provide their comments for consideration by CDSCO by filling the Google form at <a href="https://forms.gle/2jp8TmSJLypcwb2T9">https://forms.gle/2jp8TmSJLypcwb2T9</a> within 30 days from the date of publication of this document.

(Dr. Rajeev Singh Raghuvanshi)

Drugs Controller General (I)

To.

All stakeholders/associations through CDSCO website

# Google Form Link for providing comments on the Guidance document on Medical Device Software https://forms.gle/2jp8TmSJLypcwb2T9

## Central Drugs Standard Control Organization

(Medical Devices Division)

### **Guidance Document**

Title: Guidance Document on Medical Device Software

Doc No. :

**Draft for stakeholder comments** 

#### Notice:

This guidance document is aimed only for creating public awareness about Regulations of Medical Device Software and is not meant to be used for legal or professional purposes. The readers are advised to refer to the statutory provisions of Drugs and Cosmetics Act and the Medical Devices Rules, 2017 and respective Guidelines/Clarifications issued by CDSCO from time to time for all their professional needs.

#### **INDEX**

Abbreviations	i
1.0 PURPOSE	1
2.0 SCOPE	1
3.0 MODE OF SUBMISSION	1
4.0 GUIDANCE	1
4.1 KEY DEFINITIONS	2
4.2 TYPES OF MEDICAL DEVICE SOFTWARE	5
4.3 INTENDED USE STATEMENT OF MEDICAL DEVICE SOFTWARE	10
4.4 RISK-BASED CLASSIFICATION	12
4.5 APPLICABLE STANDARDS	17
4.6 REQUIREMENTS OF QUALITY MANAGEMENT SYSTEM (QMS) FOR	
MEDICAL DEVICE SOFTWARE	19
4.7 REGULATORY PATHWAY FOR MARKETING OF MEDICAL DEVICE	
SOFTWARE	20
4.8 LICENSING AUTHORITIES FOR MEDICAL DEVICE SOFTWARE	22
4.9 DOCUMENTS REQUIRED FOR GRANT OF TEST LICENCE	
FOR THE PURPOSE OF CLINICAL INVESTIGATIONS OR TEST	
OR EVALUATION OR DEMONSTRATION OR TRAINING OF MEDICAL	
DEVICE SOFTWARE, NOT FOR COMMERCIALIZATION	24
4.10 CLINICAL INVESTIGATION OF INVESTIGATIONAL MEDICAL DEVICE	
SOFTWARE AND CLINICAL PERFORMANCE EVALUATION OF	
NEW IN VITRO DIAGNOSTICS MEDICAL DEVICE SOFTWARE	25
4.11 PERMISSION TO MANUFACTURE/IMPORT INVESTIGATIONAL	
MEDICAL DEVICE/NEW IVD PRIOR TO COMMERCIALIZATION	25
4.12 DOCUMENTS REQUIRED FOR GRANT OF MANUFACTURING/IMPORT	_
LICENCE FOR SALE OR FOR DISTRIBUTION OF MEDICAL DEVICE SOFTWARE	27
	00
4.13 POST MARKETING REGULATORY REQUIREMENTS	39

Annexure A: Document checklists

#### **ABBREVIATIONS**

AE Adverse event

ACP Algorithm Change Protocol

Al Artificial Intelligence

API Application Programming Interface

CDSCO Central Drugs Standard Control Organization

CLA Central Licensing Authority

FSC Free Sale Certificate

FSCA Field Safety Corrective Action

IMS Image Management System

IVD In vitro Diagnostic(s)

LA Licensing Authority

LIS Laboratory Information System

MSC Market Standing Certificate

MDR Medical Devices Rules

NCC Non Conviction Certificate

PMS Post Marketing Surveillance

PSUR Periodic Safety Update Report

SaMD Software as a Medical Device

SiMD Software in a Medical Device

SUSAR Suspected Unexpected Serious Adverse Events

SLA State Licensing Authority

QMS Quality Management System

#### **1.0 PURPOSE**:

To provide guidance to Indian manufacturers and importers for the submission of application to the Licensing Authority (LA) for obtaining license/permission for manufacturing or import of Medical Device Software (including *In vitro* Diagnostic (IVD) Medical Device Software) under the Medical Devices Rules (MDR), 2017.

#### 2.0 SCOPE:

This guidance document applies to Software products which attract the definition of a "Medical Device" as stipulated in the MDR-2017.

This guidance document pertains to the Software categorized as follows:

- 1) Software in a medical device (SiMD).
- 2) Software as a medical device (SaMD).

This guideline reflects current practices based on MDR-2017 and should not be misconstrued as a new regulatory control on Medical Device Software (including *In vitro* Diagnostic (IVD) Medical Device Software).

#### NOTE:

For the purposes of this document, SaMD and SiMD (including IVD medical device software) shall be referred to as "Medical Device Software" hereinafter, unless otherwise specified.

#### 3.0 MODE OF SUBMISSION

- Applications for grant of Test licence for Medical Device Software shall be submitted in the National Single Window System (NSWS) portal, i.e., www.nsws.gov.in.
- Applications for grant of registration/permission/license (other than Test license) for Medical Device Software shall be submitted in the Online system for Medical Devices (MD online portal), i.e., www.cdscomdonline.gov.in.

#### 4.0 GUIDANCE

Medical Device Software are regulated under the provisions of the Drugs & Cosmetics Act, 1940 and the MDR-2017, made thereunder. Words and expressions used in this guidance document shall have the meaning respectively assigned to them in the Drugs & Cosmetics Act, 1940 and the MDR-2017 made thereunder.

#### **4.1 KEY DEFINITIONS**

- **4.1.1 "Active medical device"** means a medical device, the operation of which depends on a source of electrical energy or any other source of energy other than the energy generated by human or animal body or gravity.
- **4.1.2 "Clinical evidence"** means, in relation to,—
- (i) an *in vitro* diagnostic medical device, is all the information derived from specimen collected from human that supports the scientific validity and performance for its intended use;
- (ii) a medical device, the clinical data and the clinical evaluation report that supports the scientific validity and performance for its intended use.
- **4.1.3 "Clinical investigation"** means the systematic study of an investigational medical device in or on human participants to assess its safety, performance or effectiveness.
- **4.1.4 "Clinical performance evaluation"** means the systematic performance study of a new *in vitro* diagnostic medical device on a specimen collected from human participants to assess its performance.
- **4.1.5 "Intended use"** means the use for which the medical device is intended according to the data supplied by the manufacturer on the labelling or in the document containing instructions for use [or electronic instructions for use] of such device or in promotional material relating to such device, which is as per approval obtained from the Central Licensing Authority.

56	4.1.6 "Investigational medical device" in relation to a medical device, other
57	than in vitro diagnostic medical device, means a medical device which does
58	not have its predicate device or which is licensed under the MDR-2017 however
59	it claims for new intended use or new population or material or major design
60	change and is being assessed for safety or performance or effectiveness in a
61	clinical investigation.
62	4.1.7 "Medical Device" - All devices including an instrument, apparatus,
63	appliance, implant, material or other article, whether used alone or in
64	combination, including a software or an accessory, intended by its
65	manufacturer to be used specially for human beings or animals which does
66	not achieve the primary intended action in or on human body or animals by
67	any pharmacological or immunological or metabolic means, but which may
68	assist in its intended function by such means for one or more of the specific
69	purposes of —
70	(i) diagnosis, prevention, monitoring, treatment or alleviation of any disease
71	or disorder;
72	(ii) diagnosis, monitoring, treatment, alleviation or assistance for, any injury
73	or disability;
74	(iii) investigation, replacement or modification or support of the anatomy or of
75	a physiological process;
76	(iv) supporting or sustaining life;
77	(v) disinfection of medical devices; and
78	(vi) control of conception.
79	
80	4.1.8 "Medical device grouping" means a set of devices having same or
81	similar intended uses or commonality of technology allowing them to be
82	classified in a group not reflecting specific characteristics.
83	4.1.9 "Medical purposes" include, but are not be limited to, diagnosis,
84	prevention, monitoring, mitigation, prediction, treatment, etc., of any disease
85	or pathological condition or state.

87

4.1.10 "New in vitro diagnostic medical device" means any medical device

used for in vitro diagnosis that has not been approved for manufacture for sale

or for import by the Central Licensing Authority and is being tested to establish its performance for relevant analyte(s) or other parameter related thereto including details of technology and procedure required.

**4.1.11 "Predicate device"** means a device, first time and first of its kind, approved by the Central Licensing Authority for marketing in the country and has the similar intended use, material of construction, and design characteristics as the device which is proposed for licence in India.



88

89

90

91

92

93

#### 4.2 TYPES OF MEDICAL DEVICE SOFTWARE 96 97 Generally, Medical Device Software consists of two types: (1) Software in a medical device (SiMD) 98 (2) Software as a medical device (SaMD). 99 Not all software used within healthcare is qualified as a medical device. 100 101 Software can be considered to be active devices because they rely on a 102 source of energy other than energy generated by the human/animal body 103 or gravity. 104 4.2.1 Software in a Medical Device (SiMD) SiMD refer to software that are considered as a "part of" the medical device 105 106 hardware and that drive or influence the use of that medical device. These may also be referred to as "embedded software", "firmware", or "micro-107 108 code". 109 NOTE: SiMD drive or influence the use of a medical device, indicates that it can: 110 111 (i) operate, modify the state of, or control the device either through an interface or via the operator of the device, or 112 (ii) supply output related to the (hardware) functioning of that device. 113 114 SiMD do not have or perform a medical purpose on their own, nor are they intended to create new information on their own for any medical purposes 115 as defined in Section 4.1.9. 116 Embedded software is specialized programming in a microchip or on 117 118 firmware embedded in a medical device, either as part of a microchip or as 119 part of another application that influences the microchip – to control the 120 functioning of the device. It includes applications, firmware, middleware, 121 and operating systems that execute on a single microprocessor or cluster 122 of microprocessors "embedded" within additional logic. 123 NOTE: 124 Firmware is a type of software that provides control for a device's specific hardware. It provides the needed instructions and guidance for 125

126

the device to communicate with other devices or perform a set of basic

127 tasks and functions as intended. 128 Middleware is a type of software that lies between an operating system 129 and the applications running on it. 130 SiMD also includes software required by a hardware medical device to 131 perform the hardware's medical device intended use, even if/when sold 132 separately from the hardware medical device. Software that controls a medical device -- some software, including mobile 133 134 apps, can control or adjust a medical device through a connection, either 135 physical or utilising wireless technology such as Bluetooth or Wi--Fi 136 features. Illustration (Examples of SiMD): 137 Example (1): The embedded software/firmware in a cardiac pacemaker is 138 regulated as a component of that pacemaker, because it is supplied as part 139 140 of the device and is necessary for the device to function. Example (2): An embedded software that controls or drives an insulin pump 141 to deliver a calculated dose of insulin. 142 143 Example (3): Software that is built (pre-installed) into an IVD 144 analyser/instrument (e.g., operating software in a clinical analyser, point of care analyser or personal use IVD such as a glucose meter). In these 145 146 cases, the software is a part of a device and is not considered to be a 147 separate or distinct device. Example (4): Software that is supplied separately (which is installed on a 148 computer interface) to an IVD analyzer/instrument but intended to operate 149 or influence the IVD. In these cases, the software is a distinct IVD that is 150 151 separate from the IVD analyser/instrument. NOTE: 152 The above-mentioned examples are only suggestive of some of the different 153 154 types Medical Device Software, and are not exhaustive in nature. 155

157	•	SaMD may also be referred to as "standalone software" or "not
158		embedded/without being a part of" a hardware medical device.
159	•	SaMD are those software that are, either alone or in combination, intended
160		to be used to perform one or more medical purposes without being part of
161		a hardware medical device, wherein,
162		"without being part of" means software does not necessarily require a
163		hardware medical device to achieve its intended medical purpose.
164	•	SaMD perform a medical purpose on their own and they intended to create
165		new information on their own for any medical purposes as defined in
166		Section 4.1.9.
167	•	SaMD is capable of running on general purpose (non-medical purpose)
168		computing platforms, wherein
169		"Computing platforms" include hardware and software resources (e.g.
170		operating system, processing hardware, storage, software libraries,
171		displays, input devices, programming languages, etc.), and,
172		"Operating systems" refer to any server, workstation, mobile platform, or
173		any other general purpose hardware platform that may be required by
174		SaMD to run on.
175	•	SaMD may be interfaced with other medical devices (including hardware
176		medical devices and/or other SaMD software) as well as general purpose
177		software.
178	•	Mobile apps, AI/ML-based software and Cloud/Network-based software
179		that meet the definition stated in <b>Section 4.1.7</b> above and <b>do not drive or</b>
180		influence the use of another hardware medical device shall be
181		considered as SaMD.
182	•	Commercial off-the-Shelf (COTS) software that meet the definition as
183		stated in <b>Section 4.1.7</b> shall be considered as SaMD.
184	•	SaMD is increasingly being deployed on general-purpose (non-medical
185		purpose) hardware and delivered, in diverse care settings, on a multitude
186		of technology platforms (e.g., personal computers, smart phones, and in
187		the cloud) that are easily accessible. It is also being increasingly

4.2.2 Software as a Medical Device (SaMD)

188 189	interconnected to other systems and datasets (e.g., via networks and over the Internet).
190	Illustrations (Examples of SaMD):
191 192	Example (1): A software intended for image analysis of body fluid preparations or digital slides to perform cell count and morphology reviews.
193 194 195	Example (2): A Computer Aided Detection (CAD)-based software intended to provide information that may suggest or exclude medical conditions by analyzing X-ray images or ECGs.
196 197	Example (3): An Al/ML-based tool intended for triage, and/or screening of cancer lesions.
198	NOTE:
199 200 201	<ul> <li>The above-mentioned examples are only suggestive of some of the different types Medical Device Software, and are not exhaustive in nature.</li> </ul>
202	4.2.3 Software that are NOT covered under the MDR-2017
203 204	<ul> <li>Software that do not attract the definition of a Medical Device (as stated in Section 4.1.7 above).</li> </ul>
205	Illustrations (Examples of Software that are not SiMD/SaMD):
206 207 208	☑ Software that rely on data from a medical device, but do not have a medical purpose, e.g., software that encrypt data for transmission from a medical device.
209 210	☑ Software that monitor performance or proper functioning of a medical device for the purpose of servicing the device.
	☑ Software that alter the representation of data for embellishment/cosmetic
211 212	or compatibility purposes.
	·

data management (intended only for patient admission, for scheduling patient appointments/visits, for insurance and billing/invoicing purposes, enabling clinical communication such as voice calling, video calling, to store and transfer patient information (patient identification, vital intensive care parameters and other documented clinical observations) generated in association with the patient's treatment).

- Example Communication systems intended for general purposes, and is used for transferring both medical and non-medical information (e.g. email systems, mobile telecommunication systems, video communication systems, paging, etc.) to transfer electronic information. Different types of messages are sent such as prescription, referrals, images, patient records, etc.
- Laboratory Information Systems (LIS) are not qualified as medical devices, wherein the main intended use is the management and validation of incoming information obtained from IVD analyzers connected to the system, such as calibration, quality control, product expiry and feedback (e.g. retesting of samples needed) through interconnections with various analytical instruments (technical and clinical validation). The post-analytical process allows communication of laboratory results, statistics and optional reporting to external databases.
- Image Management System (IMS): a software-based system primarily intended to be networked with digital pathology systems, in order to access, display, annotate, manage, store, archive and share collections of digitised patient images.

#### NOTE:

The above-mentioned examples are only suggestive of some of the different types of software that may not be classified as Medical Device Software, and are not exhaustive in nature.

#### 4.3 INTENDED USE STATEMENT OF MEDICAL DEVICE SOFTWARE 244 The definition of "Intended use" means the use for which the medical 245 246 device is intended according to the data supplied by the manufacturer on the labelling or in the document containing instructions for use of such 247 device or in promotional material relating to such device, which is as per 248 approval obtained from the CLA (**Section 4.1**). 249 250 Key elements that may be considered while framing the Intended 251 Use/Intended Purpose statement for the Medical Device Software: 252 Medical Purposes (e.g., diagnosis, prevention, monitoring, mitigation a) 253 prediction, treatment, etc.) 254 b) Intended Disease or Condition (e.g., critical, serious, non-serious, etc.) 255 NOTE: The specific disease or condition intended to be targeted by the Medical 256 257 Device Software, if any, should ideally be mentioned in the intended use statement. The state of condition/disease (e.g., chronic or acute) should 258 also be considered. 259 260 c) Intended Patient Populations (e.g., general population, specific subgroup like pediatric, geriatric, specific age group, ethnicity, etc.) 261 262 d) Intended Users (e.g., non-clinical user/user without a medical qualification, 263 health care professionals that include nurses, radiologists, dentists, primary 264 care physicians, specialist care physicians, etc.) 265 e) Intended Use Environment (e.g., home use, primary care/virtual primary 266 care, hospital, specialty clinics, etc.) f) Contraindications (the specific medical conditions/comorbidities wherein 267 268 the Medical Device Software should not be used or may provide erroneous 269 results) 270 g) Medical device software function, including: 271 Medical device software inputs (e.g., from human user, medical 272 device, non-medical device, or consumer product)

Medical device software outputs (e.g., this may include clinical

273

ii.

274	interpretation or intervention (diagnosis, mitigation, treatment,
275	prediction, probability, prognosis, prescription, recommended
276	treatment/therapy, radiation treatment plans, etc.), workflow
277	recommendations (recommended surgical tools, recommended
278	additional tests, recommended imaging modality/parameters, etc.),
279	or/and data for use in medical purpose (anatomy measurements,
280	volume, or segmentation, image reconstruction/de-noising, processed
281	signals such as ECG, etc.))
282	iii. Explanation of how the medical device software inputs and
283	outputs fit into the clinical or healthcare workflow (e.g., output
284	targeted to humans or for other medical devices, whether it informs
285	clinical management, or drives it, etc.)
286	NOTE:
207	t is portinged to note that not all alaments will be applicable to all
287	It is pertinent to note that not all elements will be applicable to all  Madical Davis a Caffage.
288	Medical Device Software.
289	• For certain Medical Device Software, information such as
290	contraindications, etc. may be included elsewhere and not in the
291	intended use statement.
292	The intended use statement should be clinically meaningful and
293	measurable.
294	
295	h) In addition to the above, the following key elements should be
296	considered in the intended use statement of In-vitro diagnostic (IVD)
297	medical device software:
298	i. The analyte(s)/parameter(s) being analyzed (e.g., concentration of
299	anti-HIV antibodies, etc.)
300	ii. The type of sample/specimen to be use for analysis (e.g., blood
301	plasma, urine, etc.)
302	iii. Intended diagnostic level (e.g., screening, diagnosis aid, staging of
303	disease, prognosis, etc.)
304	iv. Limitations to the intended use, i.e., the specific
305	conditions/comorbidities/medications/analyte variant for which
306	the software may yield erroneous result, if any, (e.g., changes in

307
308
309
310
311
312
313
314
315
316
317
318
319
320
321

323

324

325

image quality may limit the efficiency by which a software analyzes stained slides; specific subtypes/variants of pathogens for which sensitivity and consequently the software performance may be affected)

v. Whether the IVD software is intended to yield quantitative, semiquantitative or qualitative results.

#### **4.4 RISK-BASED CLASSIFICATION**

 As per Rule 4 in Chapter II of the MDR-2017, all medical devices (including Medical Device Software) are classified as shown in Table 1.

Table 1. Risk classification of medical devices as per the MDR-2017.

Degree of risk	Classification
Low risk	Class A
Low moderate risk	Class B
Moderate high risk	Class C
High risk	Class D

- The risk class of the Medical Device Software is fundamentally based on the intended use of the software and the applicable parameters specified in First Schedule of MDR-2017.
- Medical Device Software, which drives a device of influences the use of a device, falls automatically in the same risk class.
- Medical Device Software, which is independent of any other medical device, is classified in its own right using the parameters specified in the First Schedule of MDR-2017.

345

346

347

348

349

350

351

352

#### 4.4.1 Factors to be considered for risk classification of SaMD

- All SaMD shall be classified using the classification parameters and provisions as specified in the First Schedule of the MDR-2017.
- The intended use of the SaMD as provided by the manufacturer shall be fundamental to the risk classification of SaMD.
- Additionally, subject to the parameters laid out in the First Schedule of MDR-2017 and as specified by the intended use statement, the following factors may be considered in determining the risk class of a SaMD:

Table 2. Risk classification of SaMD.

State of healthcare	d by SaMD to			
situation or condition	Treatment or diagnosis	Drive clinical management	Inform clinical management	
Critical	D	С	В	
Serious	С	В	А	
Non-serious	В	Α	Α	

**Note:** SaMD intended to be used by non-clinical users in a "serious situation or condition" as described here, without the support from specialized professionals, may be considered as SaMD used in a "critical situation or condition". It may, hence, influence the risk classification of the SaMD.

- a) Significance of information provided by SaMD for health care decision making, viz. Treatment or diagnosis, Drive clinical management or/and Inform clinical management.
  - **i. Treatment or diagnosis:** This infers that the information provided by the SaMD will be used to take an immediate or near term action to:
  - ☑ Treat/prevent or mitigate by connecting to other medical devices, medicinal products, general purpose actuators or other means of providing therapy to a human/animal body, or/and
  - ☑ Diagnose/screen/detect a disease or condition (i.e., using sensors, data, or other information from other hardware or software devices, pertaining to a disease or condition).
  - **ii. Drive clinical management:** This infers that the information provided by the SaMD shall be used to aid in treatment, aid in diagnoses, to triage or identify early signs of a disease or condition or/and will be used to guide next diagnostics or next treatment

353	int	terventions.
354		To aid in treatment by providing enhanced support to safe and
355		effective use of medicinal products or a medical device.
356		To aid in diagnosis by analyzing relevant information to help predict
357		risk of a disease or condition or as an aid to making a definitive
358		diagnosis.
359	☑	To triage or identify early signs of a disease or conditions.
360	iii	. Inform clinical management: This infers that the information
361	pr	rovided by the SaMD will not trigger an immediate or near term action.
362	Н	owever, the SaMD shall:
363	$\checkmark$	Inform of options for treating, diagnosing, preventing, or mitigating a
364		disease or condition, and/or
365		Provide clinical information by aggregating relevant information
366		(e.g., disease, condition, drugs, medical devices, population, etc.)
367	b) <b>Ti</b>	he health care situation or condition for which the SaMD is
368	in	tended to be used, viz. critical, serious or non-serious
369	sit	tuation/condition.
370	i.	Critical situation/condition: These refer to situations or conditions
371	wh	here accurate and/or timely diagnosis or treatment action is vital to
372	av	void death, long-term disability or other serious deterioration of health
373	of	an individual patient or to mitigating impact to public health.
374	Sa	aMD is considered to be used for a critical situation/condition when:
375	$\square$	The type of disease/condition is life threatening (including incurable
376		states), requires major therapeutic interventions, and/or time
377		critical (i.e. progression of the disease/condition is such that it may
378		affect the user's ability to reflect on the output information).
379	$\square$	Intended target population is fragile with respect to the disease or
380		condition (e.g., vulnerable population, etc.)
381	$\checkmark$	Intended for use by specialized trained users.
382	ii.	Serious situation/condition: This refers to those

situations/conditions where accurate diagnosis or treatment is of vital importance to avoid unnecessary interventions (e.g., biopsy) or timely interventions are important to mitigate long term irreversible consequences on an individual patient's health condition or public health. SaMD is considered to be used in a serious situation or condition when:

- ☑ The type of disease/condition is moderate in progression (often curable), does not require major therapeutic interventions, and/or the intervention is not expected to be time critical, in order to avoid death, long term disability or other serious deterioration of health, whereby providing the user an ability to detect erroneous recommendations.
- ✓ Intended target population is NOT fragile with respect to the disease or condition.
- ✓ Intended for use by either specialized trained users or non-clinical, untrained users.

#### NOTE:

SaMD intended to be used by non-clinical users in a "serious situation or condition" as described here, without the support from specialized professionals, may be considered as SaMD used in a "critical situation or condition".

- **iii. Non-Serious situation/condition:** This refers to a situation/condition where an accurate diagnosis and treatment is important but not critical for interventions to mitigate long term irreversible consequences on an individual patient's health condition or public health. SaMD is considered to be used in a non-serious situation or condition when:
- ☑ The type of disease/condition is slow with predictable progression
  disease states (e.g., minor chronic illness or states, etc.), may not
  be curable but can be managed effectively, requires only minor

413	interventions, and interventions are mostly non-invasive in nature,
414	providing the user the ability to detect erroneous recommendations.
415	Intended target population is individuals who may not always be
416	patients.
417	Intended for use by either specialized trained users or non-clinical,
418	untrained users.
419	The risk class shall be confirmed by CDSCO upon review of the medical
420	device details such as intended use, design characteristics, etc.
421	• In exercise of the powers conferred under sub-rule (3) of Rule 4 of MDR-
422	2017, CDSCO has classified a list of Medical Device Software and In-vitro
423	Diagnostic Medical Device Software, which are published on the CDSCO
124	website. This list is dynamic and is subject to revision from time to time
<b>1</b> 25	under the provisions of MDR-2017.
126	NOTE:
427	If several rules apply to the same device, based on the performance
428	specified for the device by the manufacturer, the strictest rules resulting in
129	the higher classification shall apply (First Schedule, MDR-2017).

#### 4.5 APPLICABLE STANDARDS 430 431 • The medical device software shall conform to the standards laid down by the Bureau of Indian Standards or as may be notified by the Ministry of 432 Health and Family Welfare in the Central Government, from time to time. 433 434 • If no such standard(s) are available, the device(s) shall conform to the 435 International Organisation for Standardisation (ISO) or the International Electro Technical Commission (IEC), or by any other pharmacopeial 436 437 standards. • In case if the standards are not specified under above points, the device 438 shall conform to the validated manufacturer's standards. 439 440 • The following standards may be applicable to all medical device software: ☑ IS/ISO 13485 standard (Medical Devices—Quality Management 441 442 Systems— Requirements for Regulatory Purposes) ☑ IS/ISO 14971 Medical devices — Application of risk management to 443 444 medical devices. ☑ IEC/TR 80002-1 Medical device software - Part 1: Guidance on the 445 446 application of ISO 14971 to medical device software. ☑ IS/ISO/TR 80002-2 Medical Device Software Part 2 Validation of 447 448 Software for Medical Device Quality Systems. ☑ IS/IEC/TR 80002-3 Medical device software Part 3: Process reference 449 450 model of medical device software life cycle processes. ☑ IS 16124 Systems and Software Engineering - Software Life Cycle 451 452 **Processes** ☑ IS/ISO/IEC 62304 Medical device software – Software life cycle 453 454 processes. 455 ☑ IS/IEC 82304-1 Health software: Part 1 general requirements for product 456 safety. ☑ IEC 81001-5-1 adds requirements about cybersecurity. 457 458 ☑ IEC 62366-1 adds requirements about man-machine interface 459 ergonomics.

Cycle Processes — Risk Management

460 461 ☑ IS 16458/ISO/IEC 16085 — Systems and Software Engineering — Life

462	☑ IS/ISO/IEC 23894 — Information Technology — Artificial Intelligence —
463	Guidance on Risk Management
464	☑ IS/ISO/IEC 42001 — Information technology — Artificial intelligence —
465	Management system
466	☑ IS/ISO/IEEE 11073 Health Informatics - Point-of-Care Medical Device
467	Communication
468	☑ ISO 24291 — Health informatics — Applications of machine learning
469	technologies in imaging and other medical applications
470	NOTE:
471	The above list mentions some of the standards that may be applicable for
., .	The above het mentione come of the diamarde that may be applicable for
472	Medical Device Software. The standard(s) that may be applicable to a

particular Medical Device Software is not limited to the list provided above.

## 4.6 REQUIREMENTS FOR QUALITY MANAGEMENT SYSTEM (QMS) FOR MEDICAL DEVICE SOFTWARE

474

475

476

477

478

479

480

481

482

483

484


485

486


487

488

- The manufacturer of a Medical Device Software need to establish Quality
  Management System (QMS) in respect of the organizational structure and
  the entire software lifecycle (design, development, product planning,
  configurations, deployment, maintenance, etc.).
- The indigenous manufacturers are required to establish and maintain procedure and records which demonstrate conformance to the requirements of QMS and submit an undertaking stating compliance with the requirements of QMS as specified in the Fifth Schedule of MDR-2017 as part of their application for grant of manufacturing license.
- In case of import, the overseas manufacturer shall ensure that their manufacturing facility complies with the QMS requirements and need to submit a notarized copy of QMS certificate issued by the National Regulatory Authority or the competent authority in their application for grant of Import license.



**Figure 1.** Flow chart illustrating the regulatory pathway to be followed for medical device software for marketing in the country.



**Figure 2.** Flow chart illustrating the regulatory pathway to be followed for IVD medical device software for marketing in the country.

496

#### 4.8 LICENSING AUTHORITIES FOR MEDICAL DEVICE SOFTWARE

499 500

501

503 504

502

 The Medical device software are required to be licenced for manufacturing or import for sale and marketing in the country by the LA as per the provisions prescribed under the MDR-2017 (Table 3 and Table 4).

**Table 3.** Licensing Authorities for grant of license/permission for manufacturing/import for marketing of medical devices in the country.

Licenses/Permissions under MDR-2017		Class A	Class B	Class C	Class D
Test license		CLA	CLA	CLA	CLA
Manufacturing I	icense	SLA	SLA	CLA	CLA
Import licence		CLA	CLA	CLA	CLA
Clinical Investig	ation of				
Investigational I	MD /Clinical				
Performance Ev	aluation of	CLA	CLA	CLA	CLA
new IVD					
Permission for manufacturing of Investigational MD/new IVD		CLA	CLA	CLA	CLA
Sale and distrib	Sale and distribution		SLA	SLA	SLA
MSC/NCC	Manufacturing	SLA	SLA	CLA	CLA
	Import	CLA	CLA	CLA	CLA
FSC (only in case of manufacturing)		SLA	SLA	CLA	CLA
Special Code		CLA	CLA	CLA	CLA

**Abbreviations:** MD: Medical Device, CLA: Central Licensing Authority, SLA: State Licensing Authority, MSC: Market Standing Certificate, NCC: Non-conviction certificate, FSC: Free Sale Certificate.

**NOTE 1:** Class A (non-sterile and non-measuring) medical devices are exempted from the licensing requirements under MDR-2017, such medical device software shall be registered as per Chapter IIIb of MDR-2017 in the MD online portal.

NOTE 2: The time line required for processing various license applications is mentioned in the MDR-2017.

#### **NOTE:**

 The applicant(s) may ensure whether the medical device software, for which application is to be submitted, is listed in the risk classification lists

531

- published by the CLA. If so, the same may be followed as risk classification for the applied devices.
- In case the medical device software has a similar intended use as the device mentioned in the published risk classification lists, they may follow the same risk classification for the applied medical device software.
- In case the medical device software is not listed in the published risk classification lists, they may seek clarification from the CLA regarding its risk classification.
- In case the medical software falls in the category of an investigational medical device (IMD) or new IVD medical device, the applicant(s) need to obtain prior permission of IMD/new IVD from the CLA under the MDR-2017 for conduct of Clinical Investigation/Clinical Performance Evaluation in the country.
- It may also be ensured that the medical device software that attract the definition of IMD or new IVD do not get approved for marketing in the country without obtaining permission from the CLA for its import/manufacturing under the MDR-2017.

# 4.9 DOCUMENTS REQUIRED FOR GRANT OF TEST LICENCE FOR THE PURPOSE OF CLINICAL INVESTIGATIONS OR TEST OR EVALUATION OR DEMONSTRATION OR TRAINING OF MEDICAL DEVICE SOFTWARE, NOT FOR COMMERCIALIZATION

- In order to obtain a Test licence (Form MD-13) to manufacture small quantities of medical device software for the purpose of Clinical Investigations or Test or Evaluation or Demonstration or Training, the applicant need to submit an online application in Form MD-12 in NSWS portal along with the requisite documents as per Rule 31 and fee as specified in the Second Schedule of MDR-2017.
- In order to obtain a Test licence (Form MD-17) to import small quantities
  of medical device software for the purpose of Clinical Investigations or
  Test or Evaluation or Demonstration or Training, the applicant needs to
  submit an online application in Form MD-16 in the NSWS portal along
  with the requisite documents as per Rule 40 and fee as specified in the
  Second Schedule of MDR-2017.
- The requisite document checklists are given in Annexure A. The list of documents required for such applications is also available in the NSWS portal.

#### NOTE:

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

The applicant may mention number of installations/number of copies/ number of downloads of the medical device software as the quantity proposed for obtaining test license.

# 4.10 CLINICAL INVESTIGATION OF INVESTIGATIONAL MEDICAL DEVICE SOFTWARE AND CLINICAL PERFORMANCE EVALUATION OF NEW IN VITRO DIAGNOSTICS MEDICAL DEVICE SOFTWARE

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

- No person or sponsor shall conduct any Clinical Investigation of an Investigational Medical device (IMD) or Clinical Performance Evaluation of new IVD on human participants or on any specimen derived from human body, respectively, except in accordance with the permission granted by the CLA as specified in MDR-2017.
- For Medical Device software that fall under the definition of an IMD or new IVD medical device, a permission to conduct Clinical investigation (Form MD-23) or Clinical Performance Evaluation (Form MD-25), respectively, is required to be obtained by the CLA by submitting an application through the MD online portal with requisite documents (Refer Rule 51 and Rule 59) and fee as specified in the Second Schedule of MDR-2017.

## 4.11 PERMISSION TO MANUFACTURE/IMPORT INVESTIGATIONAL MEDICAL DEVICE (IMD)/NEW IVD PRIOR TO COMMERCIALIZATION

- In case of IMD, a permission in Form MD-27 shall be obtained from CLA for the import/manufacture IMD prior to grant of import/manufacturing license for marketing in the country (Chapter VII, MDR-2017).
- In case of new IVD, permission in Form MD-29 shall be obtained from CLA for the import/manufacture new IVD prior to grant of import/manufacturing license for marketing in the country (Chapter VII, MDR-2017).
- The applicant shall submit application in Form MD-26 through the CDSCO MD Online portal along with requisite documents and fee as specified in the Fourth Schedule and Second Schedule, respectively, of MDR-2017 for obtaining permission in Form MD-27 for import/manufacturing of IMD in the country.
- The applicant shall submit application in Form MD-28 through the CDSCO MD Online portal along with requisite documents and fee as specified in the Fourth Schedule and Second Schedule, respectively, for obtaining permission in Form MD-29 for import/manufacturing of new IVD in the country.

589	
590	
591	
592	
593	

595

596

- In case the clinical investigation or clinical performance evaluation is conducted on such devices in India, then the clinical data generated is required to be submitted along with the above-mentioned application.
- The requisite document checklists are given in Annexure A.

#### **NOTE:**

For more details, please refer to Chapter VII and Chapter VIII of MDR-2017.



# 4.12 DOCUMENTS REQUIRED FOR GRANT OF MANUFACTURING/IMPORT LICENCE FOR SALE OR FOR DISTRIBUTION OF MEDICAL DEVICE SOFTWARE

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

- The requisite document checklists (specific to the type of licence application) for Medical Device and IVD are given in **Annexure A**.
- The applicants may refer to **Figure 1** and **Figure 2** for determining the corresponding Application Form (Legal form) number.
- In case, any of the documents specified in the checklist is deemed not applicable, then the applicant needs to submit the rationale/justification for the non-applicability of such document/requirement for Medical Device Software.
- Also, the applicant may refer the Tool Tips for information that needs
  to be filled in the Legal Form and also the technical documents that
  need to be uploaded as part of a checklist for review by the LA. The
  Tool Tips are published on the CDSCO website (www.cdsco.gov.in)

## 4.12.1 Guidance on the legal documentation applicable for medical device software

- For obtaining a licence to manufacture or import for sale and/or marketing of medical device software in the country, the applicant(s) shall submit an online application in MD online portal with the requisite fee, as specified in the Second Schedule along with respective documents as per the Fourth Schedule of MDR-2017.
- If any of the points in the Legal form is not applicable, then the applicant may mention "Not applicable" or "NA" (e.g, if shelf life is not applicable, it should be mentioned as "NA" in the Legal Form).
- The Site/Plant master file may outline the infrastructure and work environment (such as equipment, information, communication networks, tools, and the physical facility, etc.) used to support the development, production, and maintenance of the Medical Device Software. The said details need to be maintained and submitted as part of the Site/Plant Master File.
- In addition, the organization chart and personnel qualification details of the organization is also required to be submitted.

630	If any of the contents of the Site or Plant master file (as specified in
631	Appendix I, Part III of Fourth Schedule of MDR-2017) is deemed not
632	applicable, then the applicant(s) needs to submit the
633	rationale/justification for the non-applicability of such requirement for
634	Medical Device Software.
635	The manufacturers shall furnish details on company/firm constitution
636	along with a copy of the establishment/site ownership/tenancy
637	agreement. These documents shall be duly notarized.
638	<ul> <li>In case of import, the applicant shall furnish a Power of Attorney (PoA)</li> </ul>
639	along with undertaking from the authorized agent as per Part I of Fourth
640	Schedule of MDR, 2017. The PoA must be duly authenticated in India
641	either by a Magistrate of First Class or by Indian Embassy in the country
642	of origin or by an equivalent authority through apostille.
643	• The importer(s) are also required to submit a copy of the Wholesale
644	licence/Manufacturing licence/Registration Certificate in Form MD-42
645	among other requirements.
646	• The applicants are advised to go through the document checklists
647	available on the CDSCO MD Online portal (also provided in Annexure
648	A) for a complete list of legal documentation requirements.
649	4.12.2 Guidance on the technical documentation applicable for
650	medical device software
651	(A) Executive Summary - Device description, intended use,
652	specifications including variants, etc.
050	
653	Software/Firmware Description
654	Software/Firmware Description  Software description, including overview of operationally significant
654	Software description, including overview of operationally significant
654 655	Software description, including overview of operationally significant software features, analyses, inputs and outputs is required to be added in
654 655 656	Software description, including overview of operationally significant software features, analyses, inputs and outputs is required to be added in the Device Master File (DMF).
654 655 656 657	Software description, including overview of operationally significant software features, analyses, inputs and outputs is required to be added in the Device Master File (DMF).  a) Specify the name of the software
654 655 656 657 658	Software description, including overview of operationally significant software features, analyses, inputs and outputs is required to be added in the Device Master File (DMF).  a) Specify the name of the software  b) Specify the version of the software, provide a statement about software
654 655 656 657 658 659	Software description, including overview of operationally significant software features, analyses, inputs and outputs is required to be added in the Device Master File (DMF).  a) Specify the name of the software b) Specify the version of the software, provide a statement about software version naming (specify all fields and their meanings)

662	language/compiler versions used, hardware platform, operating system (if
663	applicable), use of Off-the-shelf software (if applicable), a description of
664	the software development lifecycle.
665	d) Intended User/operator of the software
666	[Examples: patient (self-use), primary caregiver, primary care physicians,
667	specialist physicians, radiologists, non-clinical user, etc.]
668	e) Intended patient population
669	[Examples: general population, specific vulnerable groups (pediatrics,
670	geriatrics), specific age group, specific ethnicity, etc.]
671	f) Intended user environment, or the setting within which the software is
672	intended to be used
673	[Examples: non-clinical environment (home use, etc.), general health care
674	(dental/general physician's clinics, primary care centers, etc.), specialty
675	health care (emergency rooms, operation theaters, oncology departments,
676	etc.)]
677	g) Analysis methodology used (if any)
678	[Examples: Rule-based calculations, online test administration, artificial
679	intelligence (AI)/machine learning (ML), neural networks, fixed or adaptive
680	algorithms]
681	h) Role of software and its output within the health care intervention
682	i. Whether the software impacts/influences or replaces any otherwise
683	manual or clinician performed actions?
684	[Examples: automated steps, triages patients, provides a definite
685	diagnosis or suggests likely diagnosis for further confirmation by
686	physician, performs or recommends treatment, identifies a region of
687	interest for further review]
688	ii. Contribution to the clinical decision
689	[Examples: intended as an aid to current practice, intended to replace
690	all or a part of a current practice, etc.]
691	iii. Whether the intended software output is dependent on other steps

692		during the health care intervention
693		[Examples: software that use output/clinical decisions from prior
694		steps such as medical image overlays and reconstruction]
695	i) So	ftware inputs and outputs
696	i.	Inputs and their format to the Medical Device Software
697		[Examples: data, images (specify modality), measurements (specify
698		units), sensor/attachments, report, questionnaire]
699	ii.	Source of the inputs.
700		[Examples: user, other medical devices, other nonmedical devices or
701		software.]
702	iii.	If the software is designed to be interoperable and transmit,
703		exchange, and/or use information through an electronic interface with
704		another medical/nonmedical product, system, or device – specify the
705		methods, standards, and specifications used.
706	iv.	Outputs and their formats: include test setup, acceptance criteria, and
707		results
708		[Examples: diagnostic information, treatment information, control
709		signals for device hardware, images (specify modality),
710		measurements (specify units), alarms, alerts, or reports, etc.]
711	V.	To whom are the outputs provided (output targets)?
712		[Examples: patients, caregivers, healthcare professionals,
713		technicians, researchers, health records, interoperable systems,
714		medical devices, etc.]
715	vi.	Data or information flow of the software
716		[Examples: inputs or outputs transmitted locally, via cloud storage, by
717		disk drive, or wirelessly]
718	vii.	Whether the software interacts with any networked devices.
719	viii.	Whether cloud or network storage is used.
720	ix.	Degree of autonomy of software (i.e., whether its output impacts

721	subsequent clinical action/decision without user intervention
722	(autonomous), or requires a user supervision (supervised autonomy),
723	or only intended as an aid for the user in clinical decision making
724	(non-autonomous).
725	j) Software change management
726	i. Degree of learning, i.e., change autonomy
727	[Examples: self-learning (autonomous updates effectuated and
728	controlled from within the software, externally controlled changes
729	(non-autonomous updates either effectuated by the user or the
730	manufacturer)
731	ii. Domain of learning or change implementation
732	[Examples: international, national, regional, patient-specific, site-
733	specific, etc.]
734	iii. Infrastructure for installation, updates and error corrections
735	[Examples: distribution channels such as app stores, web pages, web
736	application, etc., and installation locations such as mobile phones,
737	hardware medical devices, wearable devices, cloud, personal
738	computers, etc.]
739	(B) Substantial equivalence with predicate medical device software
740	The applicant(s) shall submit a substantial equivalence evidence in
741	tabular format between applied software and predicate software in
742	respect to the intended use, risk class, applicable standards, design
743	characteristics (e.g., the type of algorithm/technology used to code the software
744	(whether self-trainable, passive, machine-learning-based, procedural
745	languages, etc.), platforms for operation, nature and type of output, target user
746	of software output, training models used, if any, etc.), manufacturing and
747	testing process, performance, safety, effectiveness, and other
748	characteristics (as applicable).
749	
750	

#### (C) Essential Principles of safety and performance

- The applicant shall refer to the Essential principles checklist for demonstrating conformity to the essential principles of safety and performance of the Medical Device, published on the CDSCO website.
- While demonstrating the conformance to the essential principles, the manufacturer shall ensure the following for Medical Devices Software:
  - a) The software should be developed, manufactured and maintained in accordance with the state of the art taking into account the principles of development life cycle (e.g., rapid development cycles, frequent changes, the cumulative effect of changes), risk management (e.g., changes to system, environment, and data), including information security (e.g., safely implement updates), verification and validation (e.g., change management process).
  - b) Software that is intended to be used in combination with mobile computing platforms should be designed and developed taking into account the platform itself (e.g. size and contrast ratio of the screen, connectivity, memory, etc.) and the external factors related to their use (varying environment as regards level of light or noise).
  - c) Manufacturers should set out minimum requirements concerning hardware, IT networks characteristics and IT security measures, including protection against unauthorized access, necessary to run the software as intended.

#### (D) Risk management

The Medical Device Software are associated with some unique challenges that are generally not evident for other medical devices, which are summarized below:

- a) Direct benefit and risks for patients are not always present.
- b) Deployed on a multitude of technology/hardware platforms.
- c) Interconnected to other systems and datasets.
- d) Rapid development cycles and frequent changes.
- e) Often an update made available by the manufacturer is left to the

781

751

752

753

754

782 user of the medical device software to install. 783 f) Deployment at scale and at pace, outside control of manufacturer. 784 g) Information security with respect to safety considerations (e.g., 785 Cyber security, preservation of patient confidentiality and privacy. 786 integrity and availability of information). Local legislation and 787 regulations on data protection and privacy should be complied with. 788 h) Computer-human interaction. Considering this, the manufacturers/importers need to consider and 789 790 comply with the following: • Applicable standards such as IS/ISO 14971, IS/ISO 62304, etc. need to 791 792 be followed and complied to. • The risk management plan/protocol should be devised and the Risk 793 794 Management Report generated by the manufacturer as per the IS/ISO 795 14971 (and other applicable standards) shall be submitted as part of the license application as applicable (see Annexure A for submission 796 797 requirements). • The manufacturer/importer is required to consider and ensure 798 implementation of surveillance/monitoring mechanisms for the risks 799 800 associated with Medical device software, in relation to injury or damage to the health of people and reduction of effectiveness, wherein "reduction" 801 802 of effectiveness" can result from inadequate, incorrect, or absent data supplied to a human or product at an inappropriate time, rate, or with an 803 804 inadequate method. • The manufacturers/importers are required to consider and ensure 805 806 implementation of surveillance/monitoring mechanisms for indirect 807 harms associated with Medical Device Software (e.g., introduction of 808 unintended bias in clinical decision-making because of a Medical Device 809 Software output may be considered as an indirect harm to the patient). • The process for identification and analysis of these risks (including 810 811 indirect harms) should be considered iteratively and should be carried out over the total product lifecycle of the device. 812 813 The risk management process should be integrated across the entire 814 lifecycle of the Medical Device Software. 815 Software change management should be ensured and properly

816 documented as part of the risk management plan by the manufacturer. 817 Details on periodic updation of the Medical Device Software and 818 corrections/changes associated with risks should be added in the risk 819 management plan. 820 In this regard, an Algorithm Change Protocol (ACP) may be devised. 821 wherever applicable based on the nature and risks associated with the 822 Medical Device Software. The ACP shall include an overview of all the 823 procedures to be followed so that any changes/modifications made in 824 the Medical Device Software do not compromise its safety and intended 825 use. The ACP may contain the following information: 826 a) A data management plan that includes a data management protocol, 827 risk assessment plan, new data collection protocols, and quality 828 assurance process. b) A performance evaluation and monitoring plan, 829 describing assessment metrics, a statistical analysis plan, assessment 830 831 frequency, performance targets, and post market monitoring 832 overview. c) An algorithm retraining plan (if applicable) to described retraining 833 834 objectives, methods that will be employed to improve algorithm 835 performance, the approach to performance evaluation, and potential 836 impacts to intended purpose. 837 d) A software update plan, describing version tracking, verification and 838 validation methods, update triggers, update procedures, and approaches to transparently communicating updates to end users. 839 840 e) A rollback plan, describing triggers, backup and recovery procedures, and communication to users. 841 • The ACP may be submitted as part of the Risk Management File, if 842 843 applicable. 844 • Risks associated with process validation and benchmarking should be 845 carefully documented and assessed - including the decisions for 846 selecting specific datasets, reference standards, parameters and metrics 847 to justify such validation processes. 848 [For example, in case of Al-based SaMD, careful consideration needs to be Medical Devices Division, Central Drugs Standard Control Organization,

849 given to documenting how and why specific data or datasets are selected to 850 train, externally validate and retrain the model (e.g. post-deployment retraining).] 851 (E) Device Design System and Software Architecture Design/Diagram: 852 853 Detailed depiction of functional units and software modules may include 854 state diagrams as well as flow charts to present a roadmap of the device design to facilitate a clear understanding of: 855 856 a) The modules and layers that make up the system and software. 857 b) The relationships among the modules and layers. c) How users or external products, including IT infrastructure and 858 859 peripherals (e.g. wirelessly connected medical devices) interact with 860 the system and software. d) How users or external products, including IT infrastructure and 861 862 peripherals (e.g., wirelessly connected medical devices) interact 863 with the system and software. [Example: A module could represent – a finished hardware device within a system 864 865 of hardware and software products, a hardware component within a finished 866 hardware device, a finished software product within a system of software 867 products, or a software function within a finished software product. A module is 868 not specifically meant to describe code-level software functions.] 869 Software Requirement Specifications: 870 • The software requirement specifications (SRS) document the 871 requirements of the software. This typically includes functional 872 performance, interface design, developmental, and other requirements 873 for the software. In effect, this document describes what the Medical Device Software is supposed to do. 874 875 [Example: Hardware requirements, programming language requirements, 876 interface requirements, performance and functional requirements]

#### Software Design Specifications: 877 • The software design specifications (SDS) describe the implementation 878 879 of the requirements for the Medical Software Device. The SDS 880 describes how the requirements in the SRS are implemented. 881 (F) Software versioning and traceability The applicant(s) shall ensure traceability of the Medical Device Software 882 883 - this is essential for identification (e.g. software version) for the postmarket traceability/ follow-up (track and trace) of the software to the 884 885 users (e.g. physicians or patients) in the event of a Field Safety Corrective Action (FSCA) or product defect in post market phase. 886 Description of software versioning and traceability system implemented 887 888 for the software may be included in the Device Master File. (G) Software verification and validation 889 The Device Master File should contain information on: 890 891 The software design and development process. 892 Evidence of the validation of the software, as used in the finished device. If there are differences between the version of software that was 893 894 tested and the version in the finished device, then a description of the 895 differences and an assessment of the potential effect of the differences on the safety and effectiveness of the device needs to be submitted. 896 897 • Summary results of all verification, validation and testing performed both in-house and in a simulated or actual user environment prior to final 898 release. It should also address all of the different hardware 899 900 configurations and, where applicable, operating systems identified in the 901 labelling. 902 For Medical Device Software that work together or in conjunction with 903 other medical devices or systems, issues relating to the interoperability 904 have to be carefully considered and addressed as appropriate.

905

906

Implemented cyber security risk control methods that should be verified

and validated against specified design requirements or specifications

907	prior to implementation.
908	(H) Clinical Evidence
909	Medical Device Software may function in a way that instead of yielding
910	a direct clinical output, they provide indirect clinical benefits to the
911	subject such as:
912	a) Improving quality and consistency of care
913	b) Enhancing human abilities and mental health support
914	c) Removing administration burden
915	d) Timely care, informed decision
916	e) Earlier diagnosis and prevention
917	f) Reducing cognitive errors
918	g) Reducing burden of diagnostic and treatment activities for a patient
919	• The applicant(s) shall ensure the determination of the valid clinical
920	association/scientific validity of a Medical Device software,
921	demonstrating that it corresponds to the clinical situation, condition,
922	indication or parameter defined in its intended purpose.
923	• Types of data to support valid clinical association/scientific validity may
924	include:
925	a) Technical Standards, Literature searches
926	b) Professional medical society guidelines
927	c) Systematic scientific literature review
928	d) Clinical Investigation/Clinical performance studies
929	e) Published Clinical data
930	f) Secondary data analysis
931	• Validation of technical performance/analytical performance - to
932	demonstrate the ability of a Medical Device Software to accurately,
933	reliably and precisely generate the intended output, from the input
934	data. Evidence supporting Technical Performance/Analytical
935	Performance should be generated through verification and validation
936	activities.
937	• Validation of the Clinical Performance is the demonstration of the

938 939 940 941 942	<ul> <li>ability of a Medical Device Software to yield clinically relevant output in accordance with the intended purpose.</li> <li>Details of the Clinical Investigation/Clinical Performance evaluation (including study outcomes) of Medical Device Software may be submitted as part of the Device Master File, if applicable.</li> </ul>
943	(I) Software Labelling
944 945 946 947	<ul> <li>The Device Master File should typically contain a complete set of labelling information associated with the device as per the requirements of Chapter VI of MDR-2017.</li> <li>Generally, device labelling information includes the following:</li> </ul>
948 949 950 951 952	<ul> <li>a) Copy of original label of the device, including accessories if any, and its packaging configuration;</li> <li>b) Instructions for use (Prescriber's/User manual);</li> <li>c) Product brochure; and</li> <li>d) Promotional material.</li> </ul>
953 954 955 956 957 958	<ul> <li>The Medical Device Software should be identified with an identifier, such as version, revision level and date of build release/issue.</li> <li>Software can be supplied in different forms and there may be difficulties in presenting device information for certain forms (e.g. webbased software). Generally, software can be broadly categorised into two groups based on the mode of supply:</li> </ul>
959 960	<ul><li>a) supplied in physical form, or</li><li>b) supplied without a physical form</li></ul>
961 962 963 964 965 966	<ul> <li>If the software is delivered on a physical medium, e.g. CD or DVD, each packaging level shall bear particulars printed in indelible ink on the label, as specified in Chapter VI of MDR-2017.</li> <li>For Medical Device Software without a physical form or packaging, the instructions for use may be available electronically. In this situation, as a good practice, the device may incorporate a means for the user to easily access the electronic label via the software itself or via inclusion</li> </ul>

of a web address or other means. 968 969 The developer may display the regulatory requirement (Please refer 970 Chapter VI, MDR-2017) on the primary landing page and as a screen 971 shot in any app store. 972 A screenshot of the software graphical interface (e.g., splash screen) 973 which displays the elements for identification, including software 974 version number, may be submitted as a part of Device Master File. 975 For downloadable software where the downloading and installation is to be done by the end-user, it may be ensured that the user is provided 976 with sufficient information (e.g., Internet address/weblink to download 977 the software, software installation guide or procedure, etc.) for proper 978 979 installation of such downloadable software. 980 An appropriate system for version controls and access rights controls should be in place to allow timely tracing of the software versions. 981 982 Software lacking a user interface such as middleware for image conversion, shall be capable of transmitting the label information 983 through an Application Programming Interface (API). 984 4.13 POST MARKETING REGULATORY REQUIREMENTS 985 4.13.1 Fulfillment of conditions of license/permissions 986 The applicant is required to comply with the conditions of the 987 licence/permission as prescribed in the MDR-2017 with respect to the 988 post marketing requirements for medical devices. 989 In case any special (additional) conditions are imposed by the Licensing 990 Authority at the time of approval of the licence/permission, then the 991 applicant shall submit a condition fulfilment application through the MD 992 993 Online portal accompanied with supporting documents within the time 994 period specified by the Licensing Authority. 995 4.13.2 Post approval change notification 996 Changes to a Medical Device Software refer to any modifications made 997 throughout its lifecycle, including the maintenance phase. Medical Device Software may undergo a number of changes 998

999	t	throughout its product life cycle.
1000	• 7	The changes are typically meant to:
1001	á	a) Correct faults,
1002	k	o) Improve the software functionality and performance to meet
1003		customer demands,
1004	C	c) Keep a software product usable in a changed or changing
1005		environment.
1006	C	d) Ensure safety and effectiveness of the device is not compromised
1007		(e.g. security patch).
1008	• [	Due to the non-physical nature of software, a software change
1009	r	management process needs specific considerations to achieve the
1010	i	ntended result regarding traceability and documentation.
1011	• 1	Major changes and minor changes to medical devices are specified in
1012	t	the Sixth Schedule of MDR-2017.
1013	• 3	Subject to the provisions laid out in the Sixth Schedule of the MDR-
1014	2	2017, changes in respect of following shall be considered as major
1015	C	change in respect of Medical Device Software:
1016	6	a) Design characteristics which shall affect quality in respect of its
1017		specifications, indication for use, and performance;
1018	k	o) the intended use or indication for use;
1019		c) the name and address of, -
1020		i. the domestic manufacturer or its manufacturing site;
1021		ii. overseas manufacturer or its manufacturing site (for import
1022		only);
1023		iii. authorized agent (for import only).
1024	C	d) Label excluding change in font size, font type, colour, label design.
1025	e	e) Manufacturing process, equipment or testing which shall affect
1026		quality of the device
1027	• 3	Subject to the provisions laid out in the Sixth Schedule of the MDR-
1028	2	2017, changes in respect of following shall be considered as minor
1029		change in respect of Medical Device Software:
1030	á	a) Design which shall not affect quality in respect of its specifications,
1031		indications for use, performance and stability of the medical
1032		device.

104810491050105110521053

- b) in the manufacturing process, equipment, or testing which shall not affect quality of the device.
- c) Revisions for bug fixes and security patches, etc., which does not affect intended use, safety and performance of the medical device software.
- In case of change in constitution of the firm, which is considered as a major change, the same shall be notified to the LA as per the stipulated timeline specified under the MDR-2017 and the applicant shall submit a fresh application along with the requisite documents to obtain a new licence for marketing of Medical Device Software in the country under the MDR-2017.
- The licence holder shall submit a PAC notification/request through the MD Online portal to the CLA or the SLA, as the case may be, for any major/minor changes (including software version update) to Medical Device Software.

#### NOTE:

- In case any changes are to be made as per the approved ACP, the manufacturer/importer (on behalf of overseas manufacturer) shall submit an approval request/notification with the LA prior to implementation. A PAC approval is mandatory for major changes, while notification is required for minor changes.
- If a registered Medical Device Software has been updated such that it significantly changes the indications for use and/or the intended use of the Medical Device Software and there is an increase in its Risk class (E.g., Class B to Class C), then the applicant shall need to apply for an endorsement licence for the same.

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

### 4.12.3 Post marketing surveillance (PMS)

Once the Medical Device Software is in the market, the manufacturer/importer shall maintain vigilance for any direct/indirect harm to the user/patient(s), reduction in effectiveness, and any vulnerability to intentional and unintentional security threats as part of PMS. Manufacturers/importers should maintain documented procedure for PMS and consider the following as part of their PMS:

- Corrections and corrective actions may be required when a process is not correctly followed or the Medical Device Software does not meet its specified requirements (i.e., when a nonconforming process or product exists).
- Non-conforming Medical Device Software should be contained to prevent unintended use or delivery. The detected nonconformity should be analyzed and actions taken to eliminate the detected nonconformity (i.e., correction); and to identify and eliminate the cause(s) of the detected nonconformity (i.e., corrective action) to prevent recurrence of the detected nonconformity in the future. In some cases, a potential nonconformity may be identified, and actions such as safeguards and process changes can be taken, to prevent nonconformities from occurring (i.e., preventive action).
- Nonconformities in a Medical Device Software may lead to inaccurate or incorrect test results, mixing up of patient results, failure to deliver therapy, calibration errors resulting in incorrect patient positioning during therapy, incorrect image display, calculation errors, software bugs leading to malfunction, etc.
- A detailed procedure/plan should be devised for post-market surveillance (PMS) and response. The manufacturer/importer needs to ensure that they have the ability to handle product recalls and implement corrective actions (e.g. bug fixes, cyber alerts, software patches) in a timely and effective manner (Planning, conducting and reporting of corrective action), and to identify any recurring problems requiring attention.
- A Field Safety Corrective Action (FSCA) may be initiated when the

1124

manufacturer/importer becomes aware of such nonconformities/certain risks associated with use of the Medical Device Software through post-market monitoring and surveillance, such as through tracking of product complaints/feedback.

- Adverse events (AE) for Medical Device Software may arise due to:
  - a) Shortcomings in the design of the software
  - b) Inadequate verification and validation of the software code
  - c) Inadequate instructions for use
  - d) Software bugs introduced during implementation of new features
- The license holder shall inform the SLA or the CLA, as the case may be, of the occurrence of any suspected unexpected serious adverse event (SUSAR) and action taken thereon including any product recall within 15 days of such event coming to the notice of the license holder.
- The importer shall inform the Licensing Authority, within a period of 15 days of any administrative action taken on account of any adverse reaction, such as market withdrawal, regulatory restrictions, cancellation of authorization or declaration of the medical device as not of standard quality by the regulatory authority of the country of origin or by any regulatory authority of any other country, where the medical device is marketed, sold or distributed.
- The manufacturer/importer shall immediately inform SLA or CLA, as the case may be, if there are reasons to believe that a Medical Device Software which has been placed in the market, may be unsafe for the patients, wherein unsafe in terms of Medical Device Software refers to erroneous results leading to negative impact (whether direct or indirect) on patient health or/and introduction of bias in clinical decision-making to the extent that it may negatively impact the health of user.

[Examples: malfunction of an implanted pulse generator because of erroneous control/influence by the respective software; erroneous calculations in radiation therapy planning leading to exposure to incorrect radiation intensities, etc.].

• The manufacturer/importer shall ensure availability of sufficient infrastructure/mechanisms and resources for receiving continuous

customer/user feedback for the Medical Device Software in terms of its performance, safety and efficacy.

- The manufacturer/importer may recall a Medical Device Software from the market, subject to the conditions laid down in the MDR-2017, wherein product recall in the case of Medical Device Software may refer to a complete or partial halt in distribution of the medical device software from some or all channels/domains, uninstalling/decommissioning the Medical Device Software from some or all available networks and hardware devices.
- Medical Device Software that are approved for marketing after clinical investigation(s) (such as medical devices that do not have a predicate device), shall be closely monitored for their clinical safety once they are marketed. The manufacturer/importer(s) shall furnish Periodic Safety Update Reports (PSURs) as per the conditions laid out in the MDR-2017, in order to
  - a) Report all the relevant new information from appropriate sources;
  - b) Relate these data to patient exposure;
  - c) Summarize the market authorization status in different countries, if applicable, and any significant variations related to safety; and
  - d) Indicate whether changes will be made to product information in order to optimize the use of the product.

\*\*\*\*\*\*

#### **Annexure A: Document Checklists**

#### NOTE:

- In case any document in the given checklists is not applicable, a detailed justification with rationale for non-applicability needs to be submitted by the applicant.
- 2. In case of Class A (non-sterile and non-measuring) medical device, the applicant may obtain the registration number from the CDSCO MD Online portal to fulfill the regulatory requirements for marketing in the country.
- 3. Documents pertaining to cybersecurity verification, human factor validation, etc., may be added as a part of 'Verification and validation of medical device' checklist section.

**(A)** Checklist for the grant of **Test Licence** to manufacture medical devices for the purposes of clinical investigations or test or evaluation or demonstration or training under the Medical Devices Rules, 2017

Form Type:	Test license application in Form MD-12	? (MD)
Section no.	Checklist Name	Reference Section
1.0	Covering Letter mentioning the objective of test license	
2.0	Brief description of applied medical device including the Intended use, etc.	
3.0	Manufacturing Flow chart, Test specification and test protocol for the applied medical device(s)	
4.0	Proposed package insert/ IFU, literature, user manual, pack size and other additional document (if any)	4.9
5.0	List of equipment, instruments for manufacturing and testing of applied Medical Devices	
6.0	List of qualified personnel for manufacturing and testing of applied Medical Devices	
7.0	Justification of quantity proposed to be manufactured.	
8.0	Undertaking stating that the required facilities including equipment, instruments, and personnel have been provided to manufacture such medical devices.	
9.0	Copy of manufacturing licence of the premises where the development/testing activity is to be carried out, under these rules (if any)	
10.0	Approval letter authorizing to undertake research and development activities issued by any government organization (if any)	
11.0	Fee Challan	
12.0	Legal Form	

**(B)** Checklist for the grant of **Test Licence** to manufacture IVD medical devices for the purposes of clinical investigations or test or evaluation or demonstration or training under the Medical Devices Rules, 2017

Form Type:	Lest license application in Form MI)-12 (IVI))	
Section No.	Checklist Name	Reference Section
1.0	Covering Letter	
2.0	Brief description of the medical device including intended use, material of construction, design	
3.0	Undertaking stating that the required facilities including equipment, instruments, and personnel have been provided to manufacture such medical devices.	
4.0	List of equipment, instruments	
5.0	List of qualified personnel	
6.0	Justification of quantity proposed to be manufactured	
7.0	Test protocol, if any	4.9
8.0	Quality certificates like QMS etc., of the manufacturer from where the raw material is procured, if any	
9.0	Copy of Manufacturing licence issued under these rules, if any	
10.0	Approval letter authorizing to undertake research and development activities issued by any government organization, if any	
11.0	Other documents, if any	
12.0	Schematic plan of premises	
13.0	Certification of site with detailed raw component	
14.0	Detailed description of how the raw material will be procured so as the entire process is scrutinized	
15.0	Fee Challan	
16.0	Legal Form	

**(C)** Checklist for the grant of **Test Licence** to import medical devices (other than Class A (non-sterile and non-measuring) medical devices) for the purposes of clinical investigations or test or evaluation or demonstration or training under the Medical Devices Rules, 2017

Form Type:	Test license application in Form MD-16	6 (MD)
Section No.	Checklist Name	Reference Section
1.0	Covering Letter mentioning the objective of test license	
2.0	Brief description of the applied medical device	
3.0	Proposed package insert/ IFU, literature, user manual, pack size, Quality certificates and other additional document (if any)	
4.0	Justification of quantity proposed to be imported.	
5.0	Test specification and test protocol for the applied medical device	4.9
6.0	An undertaking stating that the medical device proposed to be imported to be used exclusively for purpose specified at serial number 7 of Form MD-16 and shall not be used for commercial purpose.	4.5
7.0	An undertaking stating that required facilities including equipment, instruments, and personnel will be provided to test or evaluate medical devices	
8.0	Fee Challan	
9.0	Legal Form	

**(D)** Checklist for the grant of **Test Licence** to import IVD medical devices for the purposes of clinical investigations or test or evaluation or demonstration or training under the Medical Devices Rules, 2017

Form Type:	Test Licence application in Form MD-16	(IVD)
Section No.	Checklist Name	Reference Section
1.0	Covering Letter mentioning the objective of test license	
2.0	Brief description of the applied medical device	
3.0	Justification of quantity proposed to be imported along with its utilization break-up	
4.0	Test specification and protocol along with applicable standards	
5.0	Quality certificates like QMS etc., of the manufacturer, if any	
6.0	Labels and IFU, as per Rule 48	
7.0	Other document, if any	4.9
8.0	An undertaking stating that the medical device proposed to be imported to be used exclusively for purpose specified at serial number 7 of Form-16 and shall not be used for commercial purpose.	
9.0	An undertaking from the testing laboratory, stating that required facilities including equipment, instruments, and personnel will be provided to test or evaluate medical devices	
10.0	Fee Challan	
11.0	Legal Form	

**(E)** Checklist for the grant of permission to conduct clinical investigation on investigational medical device(s) (other than Class A (non-sterile and non-measuring) medical devices) under the Medical Devices Rules, 2017

Form Type	Application in Form MD-22	
Sectio n No.	Checklist Name	Reference Section
1.0	Cover Letter mentioning whether the Study is Pilot/Pivotal/ Postmarketing clinical study along with its objective	
2.0	Application (Form MD-22)	
3.0	Fees Challan	
4.0	Justification for the proposed class of device along with supporting documents	
5.0	Regulatory status of the device if approved by any National regulatory authority (if any) along with the copy of approval letter	
6.0	Design analysis data of the Investigational medical device	
6.1	Design input, design output and design control documents, etc. along with design verification and validation report	
6.2	Essential Principles checklist for demonstrating conformity to the Safety and Performance of the Medical Device	
6.3	Device specification including the test parameters and its reference protocol to be carried out on the finished device along with the test report	
6.4	Mechanical test, electrical tests, Reliability tests, software verification & validation, any performance test, Ex vivo tests, etc.(wherever applicable)	
7.0	Stability Study data generated (if any)	4.10
8.0	Risk Management Report on the Investigational medical device	
9.0	Biocompatibility and Animal performance study data for Investigational medical device (as applicable)	
10.0	Proposed Labelling information	
11.0	The agreement between the Sponsor and Principal investigator	
12.0	Appropriate Insurance certificate, if any	
13.0	Forms for reporting any adverse event and serious adverse event,	
14.0	Investigators Brochure as per Seventh Schedule of MDR-2017	
15.0	Clinical Investigational Plan as per Seventh Schedule of MDR-2017	
16.0	Case Report Form as per Seventh Schedule of MDR-2017	
17.0	Informed Consent Form as per Seventh Schedule of MDR-2017	
18.0	Undertaking by the Investigator as per Seventh Schedule of MDR-2017	
19.0	Published technical documents/literature (if any)	

20.0	Clinical Investigation data generated on the applied device (if any)
21.0	Ethics Committee Approval letter
22.0	Other information (if any)

**(F)** Checklist for the grant of permission to conduct clinical performance evaluation on new IVD medical devices under the Medical Devices Rules, 2017

Form Type:	Application in Form MD-24	
Section No.	Checklist Name	Reference Section
1.0	Covering Letter	
2.0	Constitution of the Firm	
3.0	Device description including specification of raw material and finished product, data allowing identification of the device in question, proposed instruction for use, labels and regulatory status in other countries, if any	
4.0	In house performance evaluation data used to establish stability, specificity, sensitivity, repeatability and reproducibility	
5.0	Approval from an Ethics Committee	
6.0	Clinical performance evaluation plan	
7.0	Case Report Form (CRF)	
8.0	Undertaking by investigators	4.10
9.0	An undertaking that the device in question conforms to the requirements of these rules, apart from aspects covered by evaluation and apart from those specifically itemised in the undertaking, and that every precaution has been taken to protect the health and safety of the patient, user and other persons	_
10.0	Performance evaluation report from a laboratory designated under sub- rule (1) of rule 19	
11.0	Fee Challan	
12.0	Legal Form	

**(G)** Checklist for the grant of permission to import or manufacture for sale or for distribution of medical device (other than Class A (non-sterile and non-measuring) medical devices) which does not have predicate medical device under Medical Devices Rules, 2017

Form Type	Application in Form MD-26	
Section No.	Checklist Name	Reference Section
1.0	Cover Letter	
2.0	Application (Form MD-26)	
3.0	Fees Challan	
4.0	Justification for the proposed class of device along with supporting documents	
5.0	Regulatory status of the device if approved by any National regulatory authority of the countries viz. United Kingdom, United States of America, Australia, Canada, Japan, etc. along with the notarized copy of approval letter.	
6.0	Design analysis data of the Investigational medical device	
6.1	Design input, design output and design control documents, etc. along with design verification and validation report	
6.2	Essential Principles checklist for demonstrating conformity to the Safety and Performance of the Medical Device	
6.3	Device specification including the test parameters and its reference protocol to be carried out on the finished device along with the test report	4.11
6.4	Mechanical test, electrical tests, Reliability tests, software verification & validation, any performance test, Ex vivo tests, etc.(wherever applicable)	
7.0	Stability Study data generated (if any)	
8.0	Risk Management Report on the applied medical device	
9.0	Biocompatibility and Animal performance study data for applied medical device (as applicable)	
10.0	Proposed Labelling information	
11.0	In case if the device contains drug, whether the drug is approved in India, If yes, then details of approval no. and company name and validity of approval etc.,	
12.0	If the drug is not approved in India, the following documents are required to be submitted: Data on animal toxicology, Reproduction studies, Teratogenic studies, Perinatal studies, Mutagenicity, Carcinogenicity, Chemical and Pharmaceutical information, etc.	
13.0	Clinical Investigation data including that carried out in India or other countries (if any)	

14.0	Details of countries where the investigational medical device is being sold/marketed from last two year (in case of import)
15.0	Post marketing surveillance data of the investigational medical device if marketed in the countries viz. United Kingdom, United States of America, Australia, Canada, Japan, etc., from last two years.
16.0	Details on evidence that there is no theoretical possibility of any difference in the behavior and performance in Indian population
17.0	Undertaking in writing to conduct post marketing clinical investigation with the objective of safety and performance of such investigational medical device as per protocol approved by the Central Licensing Authority
18.0	Notarized copy of overseas manufacturing site or establishment or plant registration, in the country of origin issued by the competent authority (in case of import)
19.0	Constitution details of domestic manufacturer or authorized agent
20.0	Other information (if any)

**(H)** Checklist for the grant of permission to import or manufacture for sale or for distribution of IVD medical device which does not have predicate medical device under Medical Devices Rules, 2017

Form Type:	Application in Form MD-28	
Section No.	Checklist Name	Reference Section
1.0	Covering Letter	
2.0	Power of Attorney (Original) authenticated in India either by a Magistrate of First Class or by Indian Embassy in the country of origin or by an equivalent authority through apostille along with under taking from the authorized agent as specified in Part I of Forth Schedule	
3.0	Constitution details of authorized agent	
4.0	Self-attested copy of valid Whole sale licence or manufacturing licence	
5.0	Regulatory Certificates	
5.1	Notarized and valid copy of overseas manufacturing site or establishment or plant registration, by whatever name called, in the country of origin issued by the competent authority	
5.2	Notarized and valid copy of Free Sale Certificate issued by the National Regulatory Authority or equivalent competent authority of the country of origin (if any)	
5.3	Notarized and valid copy of Free Sale Certificate issued by the National Regulatory Authority or equivalent competent authority of the any of the countries namely United States of America, Australia, Canada, Japan, and European Union Countries	
5.4	Copy of latest inspection or audit report carried out by Notified bodies or National Regulatory Authority or Competent Authority within last 3 years, if any	
5.5	Copy of NOC from Department of Animal Husbandry, Ministry of Agriculture, In Case of Veterinary IVD Kits	
5.6	Copy of NOC from Bhabha Atomic Research Centre (BARC), Mumbai, In case Radio Immuno Assay Kits	4.11
6.0	Quality Management System certificate in respect of legal and actual manufacturing sites(s) (Wherever applicable)	
6.1	Notarized and valid copy of Quality Management System certificate (ISO 13485) certificate issued by the competent authority	
6.2	Notarized and valid copy of Production Quality Assurance certificate or Full quality Assurance certificate issued by the competent authority (if any)	
6.3	Notarized and valid copy of CE design certificate issued by the competent authority (if any)	
7.0	Undertaking signed by the manufacturer stating that the manufacturing site is in compliance with the provisions of the Fifth Schedule of MDR-2017	
8.0	Site or plant master file as specified in Appendix I of Fourth Schedule of MDR-2017	
9.0	Device master file as specified in Appendix III of Fourth Schedule of MDR-2017	
10.0	Device data including, (whichever is applicable)	
10.1	Design input, Design output documents, Stability data	
10.2	Device specification including specificity, Sensitivity, Reproducibility and Reputability	
10.3	Product validation and Software validation relating to the function of the Device (if any)	

11.0	Risk Management Data
12.0	Clinical Performance Evaluation data carried out in India and in other countries (if any)
13.0	Regulatory status and Restriction on use in other countries (if any) where marketed or approved
14.0	Essential principles checklist for demonstrating conformity to the essential principles of safety and performance of the in vitro medical device
15.0	Product Insert
16.0	Labelling and Pack Size
17.0	Fee Challan
18.0	Legal Form
19.0	Copy of performance evaluation report issued by the central medical device testing laboratory or medical device testing laboratory registered under sub-rule (3) of rule 83 of MDR 2017 for three batches
20.0	Stability
20.1	Claimed Shelf life - stability study report for at least 3 lots including the protocol, acceptance criteria, testing intervals and conclusion
20.2	In use stability study report for 1 lot including the protocol, acceptance criteria, testing intervals and conclusion
20.3	Shipping stability study report for 1 lot including the protocol, acceptance criteria, simulated conditions, conclusion and recommended shipping conditions
21.0	Specific evaluation report, if done by any laboratory in India, showing the sensitivity and specificity of the in vitro diagnostic medical device(if available),
22.0	Specimen batch test report for at least consecutive 3 batches showing specification of each testing parameter
23.0	Correlation chart with respect to products list mentioned in MD-28 and FSC submitted
24.0	Testing method preferably in Video (if available)

(I) Checklist for the grant of manufacturing license for Class A (other than Class A (non-sterile and non-measuring) medical devices) Medical Devices under Medical Devices Rules, 2017

Form Type:	Fresh Application (Form MD-3)		
Section no.	Checklist Name	Reference Section	
1.0	Covering Letter	4.12.1	
2.0	Legal Form (MD-3)	4.12.1	
3.0	Fee Challan	4.12.1	
4.0	Details of the constitution of the firm along with the relevant documents	4.12.1	
5.0	The Establishment /Site ownership/Tenancy Agreement	4.12.1	
6.0	Plant Master file as per Appendix I of Fourth Schedule of MDR, 2017		
6.1	General Information of the facility		
6.2	Personnel- Organisation chart		
6.3	Personnel -Qualification, Experience and responsibilities		
6.4	Premises and Facilities		
6.5	Plant Layout of premise with indication of scale	4.40.4	
6.6	List of equipment and instruments used for manufacturing and testing	4.12.1	
6.7	Sanitation		
6.8	Production		
6.9	Quality Assurance		
6.10	Storage		
6.11	Documentation		
7	Quality Management System Requirements		
7.1	Undertaking from the manufacturer stating that the manufacturing site is in compliance with the provisions of the Fifth Schedule of MDR, 2017		
7.2	Quality Manual		
7.3	Control of Documents		
7.4	Control of Records		
7.5	Management Responsibility	4.6	
7.6	Resource management	4.0	
7.7	Control of production and service provision		
7.8	Internal Audit System		
7.9	Control of non-conforming product		
7.10	Corrective Action and Preventive Action		
7.11	Table the areas showing the environmental requirement for Medical Devices as per Annexure A of Fifth Schedule of MDR, 2017.		
8.0	Copy of approval obtained from DAHD in case of devices intended for veterinary use		
9.0	Any other additional documents (if any)		
10.0	Test License obtained in Form MD-13 for the applied devices (if any)	4.9	

11.0	Copy of Permission in Form MD-27 (in case of Medical device which does not have Predicate medical device)	4.11
12.0	Device description including Intended use of the device, Material of construction (if applicable), Working principle, specification including variants and accessories etc.,	4.12.2
13.0	Labelling information (Labels, Instruction for Use, etc.)	4.12.2
14.0	Essential Principles checklist for demonstrating conformity to the Safety and Performance of the applied device Medical Device	4.12.2

# (J) Checklist for the grant of manufacturing licence for Class B Medical Devices under Medical Devices Rules, 2017

Form Type:	Fresh (Form MD-3) common checklist	
Section no.	Checklist Name	Reference Section
1.0	Covering Letter	4.12.1
2.0	Application (Form MD-3/MD-4)	4.12.1
3.0	Fee Challan	4.12.1
4.0	Details of the constitution of the firm along with the relevant documents	4.12.1
5.0	The Establishment /Site ownership/Tenancy Agreement	4.12.1
6.0	Plant Master file as per Appendix I of Fourth Schedule of MDR, 2017	
6.1	General Information of the facility	
6.2	Personnel- Organisation chart	
6.3	Personnel -Qualification, Experience and responsibilities	
6.4	Premises and Facilities	
6.5	Plant Layout of premise with indication of scale	4.40.4
6.6	List of equipment and instruments used for manufacturing and testing	4.12.1
6.7	Sanitation	
6.8	Production	
6.9	Quality Assurance	
6.10	Storage	
6.11	Documentation	
7	Quality Management System Requirements	
7.1	Undertaking from the manufacturer stating that the manufacturing site is in compliance with the provisions of the Fifth Schedule of MDR, 2017	
7.2	Quality Manual	
7.3	Control of Documents	
7.4	Control of Records	
7.5	Management Responsibility	4.0
7.6	Resource management	4.6
7.7	Control of production and service provision	
7.8	Internal Audit System	
7.9	Control of non-conforming product	
7.10	Corrective Action and Preventive Action	
7.11	Table the areas showing the environmental requirement for Medical Devices as per Annexure A of Fifth Schedule of MDR, 2017.	
8.0	Copy of approval obtained from DAHD in case of devices intended for veterinary use	
9.0	Any other additional documents (if any)	

10.0	Test License obtained in Form MD-13 for the applied devices (if any)	4.9
11.0	Copy of Permission in Form MD-27 (in case of Medical device which does not have Predicate medical device)	4.11
12.0	Device Master file in the line of Appendix II of Forth Schedule of Medical Devices Rules, 2017	
12.1	Executive Summary	
12.2	Descriptive information of the device	
12.3	Justification for the Medical Device Grouping	
12.4	Product Specification, including variants and accessories	
12.5	Substantial equivalence with reference to the predicate device or previous generations of the device	
12.6	Labelling information (Labels, Instruction for Use, etc.)	
12.7	Device Design and Manufacturing Information	
12.8	Essential Principles checklist for demonstrating conformity to the Safety and Performance of the Medical Device	
12.9	Risk analysis and control summary	
12.10	Verification and validation of the medical device	
12.11	Biocompatibility validation data (if applicable)	4.12.2
12.12	Medicinal substances data (if device contains Drug)	
12.13	Biological Safety (if applicable)	
12.14	Sterilization Validation data (if applicable)	
12.15	Software verification and validation (if software used)	
12.16	Animal studies – Preclinical data (if any)	
12.17	Stability study data (Real-time and Accelerated conditions)	
12.18	Clinical evidence (if any)	
12.19	Post Marketing Surveillance data (Vigilance reporting) duly authenticated by the manufacturer	
12.20	Batch Release Certificates or Certificate of Analysis for minimum 3 consecutive batches/ Software version release certificate/Software version release note/Software release report	

## **(K)** Checklist for the grant of manufacturing licence for Class A and Class B IVD Medical Devices under Medical Devices Rules, 2017

Form Type:	Fresh Application (Form MD-3)	
Section No.	Checklist Name	Reference Section
1.0	Covering Letter	4.12.1
2.0	Constitution Details of Manufacturer	4.12.1
3.0	Site or plant master file as specified in Appendix I of Fourth Schedule of MDR 2017	4.12.1
4.0	Device master file as specified in Appendix III of Fourth Schedule of MDR 2017	4.12.2
5.0	Essential principles checklist for demonstrating conformity to the essential principles of safety and performance of the in vitro medical device	4.12.2
6.0	Undertaking signed by the manufacturer stating that the manufacturing site is in compliance with the provisions of the Fifth Schedule of MDR 2017	4.6
7.0	Labelling and Pack Size	4.12.2
8.0	Regulatory Certificates	4.12.1
8.1	Copy of latest inspection or audit report carried out by Notified bodies or National Regulatory Authority or Competent Authority within last 3 years, if any	
8.2	Valid copy of Quality Management System certificate (ISO:13485) certificate issued by the competent authority (if any)	
8.3	Copy of NOC from Department of Animal Husbandry, Ministry of Agriculture, In Case of Veterinary IVD Kits (if available)	
8.4	copy of NOC from Bhabha Atomic Research Centre (BARC), Mumbai, In case Radio Immuno Assay Kits (if available)	
8.5	Copy of Test licence obtained for testing and generation of quality control data, if any	4.9
8.6	Self-attested copy of valid Whole sale licence or manufacturing licence if any	
9.0	Specific evaluation report, if done by any laboratory in India, showing the sensitivity and specificity of the in vitro diagnostic medical device (For class B medical devices) (if available)	4.12.2
10.0	Specimen batch test report for at least consecutive 3 batches showing specification of each testing parameter (For class B medical devices)	
11.0	Copy of performance evaluation report issued by the central medical device testing laboratory or medical device testing laboratory registered under sub-rule (3) of rule 83 of MDR 2017 for three batches (For class B medical devices)	

12.0	A summary of analytical technology, relevant analytes and test procedure (For class A medical devices)	
13.0	Working principle and use of a novel technology (For class A medical devices) (if any)	4.12.2
14.0	Stability	
14.1	Claimed Shelf life - stability study report for at least 3 lots including the protocol, acceptance criteria, testing intervals and conclusion.	
14.2	In use stability study report for 1 lot including the protocol, acceptance criteria, testing intervals and conclusion,	
14.3	Shipping stability study report for 1 lot including the protocol, acceptance criteria, simulated conditions, conclusion and recommended shipping conditions	
15.0	Product Insert	4.12.1
16.0	Fees Challan	4.12.1
17.0	Legal Form	4.12.1

## **(L)** Checklist for the grant of manufacturing license for Class C and Class D Medical Devices under Medical Devices Rules, 2017

Form Type: Fresh application in Form MD-7				
Section No.	Checklist Name	Reference Section		
1.0	Covering Letter	4.12.1		
2.0	Application form	4.12.1		
3.0	Fee Challan	4.12.1		
4.0	Details of the constitution of the firm along with the relevant documents	4.12.1		
5.0	The Establishment /Site ownership /Tenancy Agreement	4.12.1		
6.0	Plant Master file as per Appendix I of Fourth Schedule of MDR, 2017			
6.1	General Information of the facility			
6.2	Personnel- Organisation chart			
6.3	Personnel -Qualification, Experience and responsibilities			
6.4	Premises and Facilities			
6.5	Plant Layout of premise with indication of scale	4.12.1		
6.6	List of equipment and instruments used for manufacturing and testing	4.12.1		
6.7	Sanitation			
6.8	Production			
6.9	Quality Assurance			
6.10.	Storage			
6.11	Documentation			
7.0	Quality Management System Requirements			
7.1	Undertaking from the manufacturer stating that the manufacturing site is in compliance with the provisions of the Fifth Schedule of MDR, 2017			
7.2	Quality Manual			
7.3	Control of Documents			
7.4	Control of Records			
7.5	Management Responsibility	4.6		
7.6	Resource management			
7.7	Control of production and service provision			
7.8	Internal Audit System			
7.9	Control of nonconforming product			
7.10	Corrective Action and Preventive Action			
7.11	Table the areas showing the environmental requirement for Medical Devices as per Annexure A of Fifth Schedule of MDR, 2017.			
8.0	Device Master file in the line of Appendix II of Fourth Schedule of MDR, 2017	4.12.2		
8.1	Executive Summary			

8.2	Descriptive information of the device	
8.3	Justification for the Medical Device Grouping	
8.4	Product Specification, including variants and accessories	
8.5	Substantial equivalence with reference to the predicate device or previous generations of the device	
8.6	Labelling information (Labels, Instruction for Use, etc)	
8.7	Device Design and Manufacturing Information	
8.8	Essential Principles checklist for demonstrating conformity to the Safety and Performance of the Medical Device	
8.9	Risk analysis and control summary	
8.1	Verification and validation of the medical device	
8.11	Biocompatibility validation data (if applicable)	
8.12	Medicinal substances data (if device contains Drug)	
8.13	Biological Safety (if applicable)	
8.14	Sterilization Validation data (if applicable)	
8.15	Software verification and validation (if software used)	
8.16	Animal studies – Preclinical data (if any)	
8.17	Stability study data (Real-time and Accelerated conditions)	
8.18	Clinical evidence (if any)	
8.19	Post Marketing Surveillance data (Vigilance reporting)	
8.20	Batch Release Certificates or Certificate of Analysis for minimum 3 consecutive batches/ Software version release certificate/Software version release note/Software release report	
9.0	Copy of approval obtained from DAHD in case of devices intended for veterinary use	
10.0	Any other additional documents (if any)	
11.0	Test License obtained in Form MD-13 for the applied devices (if any)	4.
12.0	Copy of Permission in Form MD-27 (in case of Medical device which does not have Predicate medical device)	4.

## (M) Checklist for the grant of manufacturing license for Class C and Class D IVD under Medical Devices Rules, 2017

Form Type:	Fresh application in Form MD-7	
Section No.	Checklist Name	Reference Section
1.0	Covering Letter	4.12.1
2.0	Constitution Details of Manufacturer,	4.12.1
3.0	Site or plant master file as specified in Appendix I of Fourth Schedule of MDR 2017	
3.1	Part–1 Plant Layout of premise with indication of scale	
3.2	Part-2 Organization chart showing the arrangements for key personnel	4.12.1
3.3	Part-3 Qualification, Experience and responsibilities of key Technical Persons	
3.4	Part-4 List of Equipment and Instruments	
3.5	Part-5 Contract Activities if any	
4.0	Quality Management System	
4.1	Part – 1 Quality Management System as per Fifth Schedule of Medical devices Rules, 2017	
4.2	Part – 2 Quality Manual	
4.3	Part – 3 Quality Policy	
4.4	Part – 4 Control of Documents	
4.5	Part – 5 Control of Records	
4.6	Part – 6 Management Responsibility	4.6
4.7	Part – 7 Internal Audit System	
4.8	Part – 8 Preventive and Corrective Action	
4.9	Part – 9 Procedure for identifying training needs and ensure that all persons are trained to adequately perform their assigned responsibilities.	
4.10	Part – 10 Table the areas showing the environmental requirement for Medical Devices as per Annexure A of Fifth Schedule of Medical devices Rules, 2017	
5.0	Undertaking signed by the manufacturer stating that the manufacturing site is in compliance with the provisions of the Fifth Schedule of MDR 2017	4.6
6.0	Regulatory certificates	4.6, 4.9

6.1	Copy of latest inspection or audit report carried out by Notified bodies or National Regulatory Authority or Competent Authority within last 3 years	
6.2	Copy of NOC from Department of Animal Husbandry, Ministry of Agriculture, In Case of Veterinary IVD Kits (if available)	
6.3	Copy of NOC from Bhabha Atomic Research Centre (BARC), Mumbai, In case Radio Immuno Assay Kits (if available)	
6.4	Valid copy of Quality Management System certificate (ISO:13485) certificate issued by the competent authority .(if any)	
6.5	Copy of Test licence obtained for testing and generation of quality control data, if any	
6.6	Self attested copy of valid Whole sale licence or manufacturing licence, if any	
7.0	Device Master File for In Vitro Diagnostic Medical Devices as per Appendix–III of Part III of Fourth Schedule of Medical devices Rules, 2017	
7.1	Part – 1 Executive Summary	
7.2	Part-2 Regulatory status of the similar device in India (approved or new in vitro diagnostic medical device).	
7.3	Part-3 Description and specification, including variants and accessories of the in vitro diagnostic medical device	
7.4	Part – 4 Essential principles checklist for demonstrating conformity to the essential principles of safety and performance of the in vitro medical device	
7.5	Part – 5 Risk analysis and control summary	
7.6	Part–6 Device Design and Manufacturing Information	
7.7	Part-7 Product validation and verification	
7.8	Part-8 Analytical studies, Specimen type, Analytical performance characteristics, Analytical sensitivity, Analytical Specificity, Metrological traceability of calibrator and control material values, Measuring range of assay, Definition of assay	4.12.2
7.9	Part – 9 Claimed Shelf life - stability study Report for at least 3 lots including the protocol, acceptance criteria, testing intervals and conclusion.	
7.10	Part-10 In use stability study report for 1 lot including the protocol, acceptance criteria, testing intervals and conclusion for	
7.11	Part-11 Shipping stability study report for 1 lot including the protocol, acceptance criteria, testing intervals and conclusion for Part-11Shippingstabilitystudyreportfor1 lot including the protocol, acceptance criteria, testing intervals and conclusion for	
7.12	Part-12 Clinical Evidence	
7.13	Part-13 Product Insert, Pack size, Label	
7.14	Part-14 Specimen batch test report format least consecutive 3 batches showing specification of each testing parameter	

7.15	Part-15 Specific evaluation report, if done by any laboratory in India, showing the sensitivity and specificity of the invitro diagnostic medical device	
7.16	Part-16 Copy of performance evaluation report issued by the central medical device testing laboratory or medical device testing Laboratory registered under sub-rule(3)of rule 83 of MDR 2017 for three batches	
7.17	Part-17 Post Market Surveillance Data	
7.18	Part-18-Others	
8.0	Fee Challan	4.12.1
9.0	Legal Form	4.12.1

## **(N)** Checklist for the grant of Import license for Medical Device under Medical Devices Rules, 2017

Form Type:	Fresh application in Form MD-14	
Section no.	Checklist Name	Reference Section
1	Covering Letter	4.12.1
2	Application (Form MD-14)	4.12.1
3	Fee Challan	4.12.1
4	Power of Attorney along with undertaking from the authorized agent as per Part I of Fourth Schedule of MDR, 2017 (duly authenticated in India either by a Magistrate of First Class or by Indian Embassy in the country of origin or by an equivalent authority through apostille)	4.12.1
5	Copy of Whole Sale licence / Manufacturing licence/ Registration Certificate in Form MD-42 of the Authorized agent	4.12.1
6	Constitution details of the authorized agent	4.12.1
7	Regulatory Certificate	
7.1	Copy of Free Sale Certificate/Marketing Authorization of the product issued by the National Regulatory Authority of country of origin (if any) (duly notarized)	4.12.1
7.2	Copy of Free Sale Certificate Marketing Authorization of the product issued from National Regulatory Authority of any of the following countries viz., USA, UK, EU, Canada, Japan or Australia (duly notarized)	
7.3	Copy of overseas manufacturing site / establishment / plant registration, by whatever name called, in the country of origin issued by the competent authority (duly notarized)	
7.4	Copy of latest inspection or audit report carried out by the Competent Authority within last 3 years, if any.	
8	Quality Certificate in respect of the actual manufacturing site, as applicable	4.6
8.1	Copy of Certificate supporting Quality Management System (duly notarized)	
8.2	Copy of Full Quality Assurance Certificate/ CE type examination Certificate/ CE product quality assurance certificate, CE design Certificate, etc. as applicable (duly notarized)	
8.3	Declaration of conformity issued by the manufacturer	
9	Plant Master file from the Manufacturer as per Appendix I of Fourth Schedule of Medical Devices Rules, 2017	4.12.1
10	Device Master file from the Manufacturer as per Appendix II of Fourth Schedule of Medical Devices Rules, 2017	4.12.2
10.1	Executive Summary	

10.2	Descriptive information of the device
10.3	Justification for the Medical Device Grouping
10.4	Product Specification, including variants, accessories, etc.
10.5	Substantial equivalence with reference to the predicate device or previous generations of the device
10.6	Labelling information (Labels, Instruction for Use, etc.)
10.7	Device Design and Manufacturing Information
10.8	Essential Principles checklist for demonstrating conformity to the Safety and Performance of the Medical Device
10.9	Risk analysis and control summary
10.10	Verification and validation of the medical device
10.11	Biocompatibility validation data (if applicable)
10.12	Medicinal substances data (if device contains Drug)
10.13	Biological Safety (TSE/BSE), if applicable
10.14	Sterilization Validation data (if applicable)
10.15	Software verification and validation (if software used)
10.16	Animal studies – Preclinical data (if any)
10.17	Stability study data (Real-time and Accelerated conditions) for the claimed shelf life (if applicable)
10.18	Clinical evidence (if any)
10.19	Post Marketing Surveillance data (Vigilance reporting)
10.20	Batch Release Certificates or Certificate of Analysis for minimum 3 consecutive batches/ Software version release certificate/Software version release note/Software release report
11	Any other additional documents
12	Copy of Permission in Form MD-27 (in case of Investigational Medical Device)

Form Type:	Fresh Application in Form MD-14	
Section No.	Checklist Name	Reference Section
1.0	Covering Letter	4.12.1
2.0	Power of Attorney (Original) authenticated in India either by a Magistrate of First Class or by Indian Embassy in the country of origin or by an equivalent authority through apostille along with undertaking from the authorized agent as specified in Part I of Fourth Schedule	4.12.1
3.0	Self-attested copy of valid Wholesale licence or manufacturing licence, if any	4.12.1
4.0	Regulatory Certificates along with previous import license (if any)	4.12.1
4.1	Notarized copy of overseas manufacturing Site or establishment or plant registration, by whatever name called, in the country of origin issued by the competent authority	
4.2	Notarized and valid copy of Free Sale Certificate issued by the National Regulatory Authority or equivalent competent authority of the country of origin (if any)	
4.3	Notarized and valid copy of Free Sale Certificate issued by the National Regulatory Authority or equivalent competent authority of the any of the countries namely United States of America, Australia, Canada, Japan, and European Union Countries	
4.4	Copy of latest inspection or audit report Carried out by Notified bodies or National Regulatory Authority or Competent Authority within last 3 years, if any.	
4.5	Copy of NOC from Department of Animal Husbandry, Ministry of Agriculture, In Case of Veterinary IVD Kits,	
4.6	Copy of NOC from Bhabha Atomic Research Centre (BARC), Mumbai, In case Radio Immuno Assay Kits	
5.0	Quality Management System certificate in respect of legal and actual manufacturing sites(s) (Wherever applicable)	4.6
5.1	Notarized and valid copy of Quality Management System certificate (ISO13485) certificate issued by the competent authority,	
5.2	Notarized and valid copy of Production Quality Assurance certificate or Full quality Assurance certificate issued by the competent authority.(if any)	
5.3	Notarized and valid copy of CE design certificate issued by the competent authority.(if any),	
6.0	Site or plant master file as specified in Appendix I of Fourth Schedule of MDR-2017	4.12.1
7.0	Device Master File for In Vitro Diagnostic Medical Devices as per Appendix–III of Part III of Fourth Schedule of Medical devices Rules, 2017	4.12.2

7.1	Part-1 Executive Summary, Description and specification, including variants and accessories and Design & manufacturing information of the in-vitro diagnostic medical device	
7.2	Part-2 Regulatory status of the similar device in India (approved or new in vitro diagnostic medical device).	
7.3	Part–3 Essential principles checklist	
7.4	Part–4 Risk analysis and control summary, Product validation and verification and Clinical Evidences	
7.5	Part-5 Analytical studies, Specimen type, Analytical performance characteristics, Analytical sensitivity, Analytical Specificity, Metrological traceability of calibrator and control material values, Measuring range of assay, Definition of assay	
7.6	Part – 6 Claimed Shelf life – stability study report for at least 3 lots including the protocol, acceptance criteria, testing intervals and conclusion, In use stability study report for 1 lot including the protocol, acceptance criteria, testing intervals and conclusion & Shipping stability study report for 1 lot including the protocol, acceptance criteria, testing intervals and conclusion.	
7.7	Part-7 Product Insert, Pack size, Label	
7.8	Part-8 Specimen batch test report for at least consecutive 3 batches showing specification of each testing parameter	
7.9	Part-9 Copy of performance evaluation Report issued by the central medical device testing laboratory o r medical device testing laboratory registered under sub-rule (3) of rule 83 of MDR 2017 for three batches/ Specific evaluation report, if done by any laboratory in India, showing the sensitivity and specificity of the in-vitro diagnostic medical device	
7.10	Part-10 Post Market Surveillance Data and any other information of the product	
8.0	Correlation chart with respect to products list mentioned in MD-14 and FSC submitted	
9.0	Testing method preferably in Video (if available)	
10.0	Fee Challan	4.12.1
11.0	Legal Form	4.12.1